Business Context and Reporting Period
D. Boral ARC Acquisition I Corp. (BCAR) is a blank check company incorporated in the British Virgin Islands on March 20, 2025, formed to effect a business combination. The filing covers the fiscal year ended December 31, 2025. The Company consummated its Initial Public Offering (IPO) on August 1, 2025, raising gross proceeds of $280,000,000 (including partial over-allotment). As of the filing date, the Company has not commenced operations and is classified as a shell company and an emerging growth company.
Key Financial Metrics
| Metric | Value (as of Dec 31, 2025) |
|---|---|
| Revenue | $0 (No operating revenue) |
| Net Income | $4,455,970 |
| Operating Costs | $(320,658) |
| Interest Income (Trust Account) | $4,776,628 |
| Cash (Operating) | $420,340 |
| Cash in Trust Account | $284,776,628 |
| Working Capital | $585,863 |
| Total Liabilities | $37,611 (Accrued expenses) |
| Shares Outstanding | 28,000,000 Class A (Public); 12,000,000 Class B (Founder) |
Material Changes and Recent Developments
- Proposed Business Combination: On January 11, 2026 (subsequent to the reporting period), the Company entered into a Merger Agreement to acquire Exascale Labs Inc. The aggregate consideration is $500,000,000, payable in newly issued shares valued at $10.00 per share.
- Trust Account Growth: Funds in the trust account increased from the initial $280,000,000 to approximately $284,776,628 due to interest income earned on U.S. government treasury obligations.
- Over-Allotment: Underwriters partially exercised the over-allotment option on August 11, 2025, purchasing 3,000,000 additional units. The remaining option was forfeited on September 9, 2025, resulting in the cancellation of 321,429 founder shares.
Outlook, Risks, and Management Commentary
- Going Concern: The independent auditor has expressed substantial doubt about the Company's ability to continue as a going concern. The Company has limited operating cash ($420,340) and relies on the completion of a business combination or additional financing to sustain operations.
- Liquidity: The Company has no long-term debt. It may obtain working capital loans from the Sponsor or affiliates up to $2,500,000, which may be convertible into private units. No such loans were outstanding as of December 31, 2025.
- Extension Rights: The Company has 18 months from the IPO closing (August 1, 2025) to consummate a business combination, with one optional three-month extension available at the Sponsor's discretion. If no combination is completed, the Company will liquidate and redeem public shares.
- Conflicts of Interest: Management and the Sponsor have significant conflicts of interest regarding the selection of a target, as they hold founder shares and private units that could expire worthless if no transaction occurs. They have waived redemption rights for these holdings.
Investor Verification Checklist
- Merger Agreement Status: Verify the current status of the proposed merger with Exascale Labs Inc. announced in January 2026, including shareholder approval requirements and closing conditions.
- Trust Account Balance: Confirm the current balance in the trust account and the per-share redemption value, which may fluctuate based on interest rates and tax liabilities.
- Going Concern Resolution: Assess the Company's ability to secure additional working capital if the merger is delayed or if operating expenses exceed the current $420,340 cash balance.
- Redemption Rights: Review the specific terms regarding public shareholder redemption rights in connection with the proposed business combination.
- Related Party Transactions: Monitor any future working capital loans from the Sponsor or affiliates and the terms of their conversion into equity.